Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
22.50    1.00 (4.65%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £31.18m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Director Shareholding

9 Mar 2017 07:00

RNS Number : 9294Y
Sareum Holdings PLC
09 March 2017
 

(AIM: SAR)

9 March 2017

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Director shareholding

Sareum announces that Dr. Stephen Parker, Sareum's Chairman, and his wife purchased 461,949 and 674,272 shares at 0.95p each respectively yesterday. These are the only shares that Dr Parker or his wife own in the Company. Dr Parker's shareholding represents 0.017% of the Company's issued share capital and Dr Parker's wife's shareholding represents 0.025% of the Company's issued share capital.

 

For further information, please contact:

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / Nick Prowting

020 7220 1666

Hybridan LLP (Co-Broker)

 

Claire Noyce / William Lynne

020 3764 2341/2342

The Communications Portfolio (Sareum Media enquiries)

 

Ariane ComstiveAriane.comstive@communications-portfolio.co.uk 

07785 922 354

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Dr. Stephen Parker

2

Reason for the notification

a)

Position/status

Chairman, Sareum Holdings plc

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Sareum Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 0.025p each

 

 

GB00B02RFS12

b)

Nature of the transaction

Purchase of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

0.95p

Dr. Stephen Parker: 461,949 shares

Susan Parker: 674,272 shares

Total: 1,136,221 shares

 

d)

Aggregated information

- Aggregated volume

- Price

 

1,136,2210.95p

e)

Date of the transaction

8 March 2017

f)

Place of the transaction

London Stock Exchange, AIM

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHJPMMTMBTMTTR
Date   Source Headline
1st May 20267:00 amRNSExercise of Warrants
12th Mar 20267:00 amRNSHalf-Year Report for Six Months Ended 31 Dec 2025
12th Mar 20267:00 amRNSHalf-Year Report for Six Months Ended 31 Dec 2025
3rd Mar 20267:00 amRNSNotice of Results and Investor Presentation
17th Feb 20267:00 amRNSRestart of Phase 2-enabling toxicology programme
23rd Jan 20264:36 pmRNSForm 8.3 - Oxford Biomedica plc
9th Dec 20254:25 pmRNSResults of AGM
9th Dec 20257:00 amRNSAnnual General Meeting Statement
17th Nov 20257:00 amRNSNotice of AGM, Annual Report and Accounts
30th Oct 20257:00 amRNSAppointment of Joint Corporate Broker
23rd Oct 20257:00 amRNSPreliminary Results for Year Ended 30 June 2025
10th Oct 20257:00 amRNSUpdate on toxicology study for SDC-1801
7th Oct 20257:00 amRNSNotice of Results and Investor Presentation
26th Sep 20253:12 pmRNSExercise of Warrants
18th Sep 202512:59 pmRNSExercise of Warrants
26th Aug 20257:00 amRNSExercise of Warrants
20th Aug 202510:01 amRNSExercise of Warrants
12th Aug 20257:00 amRNSSareum Collaboration with Receptor.AI
9th Jul 20257:00 amRNSExercise of Warrants
4th Jul 20257:00 amRNSAppointment of Sole Broker
29th May 20257:00 amRNSInitiation of Toxicology Studies for SDC-1801
28th Apr 20257:00 amRNSUpdate on TYK2/JAK1 and SRA737 Programmes
24th Apr 20257:00 amRNSExercise of Warrants
27th Mar 20257:00 amRNSDirector’s Dealing
25th Mar 20257:00 amRNSSareum Half-Year Report
20th Mar 20257:00 amRNSNotice of HY Results and Investor Presentation
13th Mar 20257:15 amRNSInstitutional Equity Fundraise
13th Mar 20257:08 amRNSSareum Acquires Licence for SRA737
31st Dec 20247:00 amRNSUpdate on SRA737
19th Dec 20244:07 pmRNSResults of AGM
19th Dec 20247:00 amRNSAGM Statement
18th Dec 20247:00 amRNSAppointment of Joint Broker
17th Dec 20249:14 amRNSHolding(s) in Company
16th Dec 20247:00 amRNSAward of Share Options
27th Nov 20249:38 amRNSNotice of AGM, Annual Report and Accounts
29th Oct 20247:00 amRNSFinal Results for the Year Ended 30 June 2024
23rd Oct 20247:00 amRNSNotice of Final Results and Investor Presentation
21st Oct 20247:00 amRNSFurther Subscription to raise £1,000,000
11th Oct 20247:00 amRNSSubscription to raise £2,364,000
16th Sep 20247:00 amRNSPatent Allowance in China
2nd Sep 20247:00 amRNSUS patent allowance
10th Jul 20247:00 amRNSManagement Changes
1st Jul 20247:00 amRNSPositive Data from SDC-1801 Phase 1 Clinical Trial
30th May 20247:00 amRNSAppointment of Sole Broker
7th May 20242:10 pmRNSExercise of Warrants
23rd Apr 20247:00 amRNSFinal Issue of RiverFort Subscription Shares
19th Apr 202411:35 amRNSIssue of RiverFort Subscription Shares
15th Apr 20243:28 pmRNSIssue of RiverFort Subscription Shares
9th Apr 20244:00 pmRNSIssue of RiverFort Subscription Shares
4th Apr 20242:38 pmRNSCompletion of Equity Fundraise

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.